Electrical impedance myography for assessment of Duchenne muscular dystrophy
- 11 January 2017
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 81 (5) , 622-632
Abstract
Objective: Sensitive, objective, and easily applied methods for evaluating disease progression and response to therapy are needed for clinical trials in Duchenne muscular dystrophy (DMD). In this study, we evaluated whether electrical impedance myography (EIM) could serve this purpose.Methods: In this nonblinded study, 36 boys with DMD and 29 age‐similar healthy boys underwent multifrequency EIM measurements for up to 2 years on 6 muscles unilaterally along with functional assessments. A linear mixed‐effects model with random intercept and slope terms was used for the analysis of multifrequency EIM values and functional measures. Seven DMD boys were initiated on corticosteroids; these data were analyzed using a piecewise linear mixed‐effects model.Results: In boys > 7.0 years old, a significant difference in the slope of EIM phase ratio trajectories in the upper extremity was observed by 6 months of −0.074/month, p = 0.023, 95% confidence interval (CI) = −0.013, −0.14; at 2 years, this difference was −0.048/month, p < 0.0001, 95% CI = −0.028, −0.068. In boys ≤ 7.0 years old, differences appeared at 6 months in gastrocnemius (EIM phase slope = −0.83 °/kHz/mo, p = 0.007, 95% CI = −0.26, −1.40). EIM outcomes showed significant differences earlier than functional tests. Initiation of corticosteroids significantly improved the slope of EIM phase ratio (0.057/mo, p = 0.00019, 95% CI = 0.028, 0.086) and EIM phase slope (0.14 °/kHz/mo, p = 0.013, 95% CI = 0.028, 0.25), consistent with corticosteroids' known clinical benefit.Interpretation: EIM detects deterioration in muscles of both younger and older boys by 6 months; it also identifies the therapeutic effect of corticosteroid initiation. Because EIM is rapid to apply, painless, and requires minimal operator training, the technique deserves to be further evaluated as a biomarker in DMD clinical therapeutic trials. Ann Neurol 2017;81:622–632Keywords
Funding Information
- National Institutes of Health (R01AR060850)
This publication has 35 references indexed in Scilit:
- The 6‐minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter studyMuscle & Nerve, 2013
- 24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular DystrophyPLOS ONE, 2013
- Pentoxifylline as a rescue treatment for DMDNeurology, 2012
- Electrical impedance myography for monitoring motor neuron loss in the SOD1 G93A amyotrophic lateral sclerosis ratClinical Neurophysiology, 2011
- Electrical impedance myography in spinal muscular atrophy: A longitudinal studyMuscle & Nerve, 2011
- Characterizing spinal muscular atrophy with electrical impedance myographyMuscle & Nerve, 2010
- Electrical characteristics of rat skeletal muscle in immaturity, adulthood and after sciatic nerve injury, and their relation to muscle fiber sizePhysiological Measurement, 2009
- Electrical impedance myography: Background, current state, and future directionsMuscle & Nerve, 2009
- Electrical impedance myography at 50 kHz in the rat: Technique, reproducibility, and the effects of sciatic injury and recoveryClinical Neurophysiology, 2009
- Statistical significance for genomewide studiesProceedings of the National Academy of Sciences, 2003